ClinicalTrials.gg
CompletedNCT06196879Updated May 1, 2026

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

A Phase 2 interventional study of Verekitug (UPB-101) and Placebo in Severe Asthma, sponsored by Upstream Bio Inc.. Completed at 155 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Upstream Bio Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
228th of 1,353
479 · median 100
Started
2024
with 50 others
Phase 2
292 of 1,695
22 open now
Registered
1,564th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 228th largest by enrollment of the 1,353 interventional ones that give a count, is one of 51 that started in 2024, is one of 292 in phase 2, and was the 1,564th registered.

Asthma

4,846 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.

Read the detailed description

This is a multicenter, randomized, placebo-controlled, parallel group study to assess the efficacy and safety of verekitug (UPB-101) administered subcutaneously (SC). A total of approximately 436 adult participants with severe asthma are planned for enrolment and will be randomized in a 1:1:1:1 ratio to receive verekitug (UPB-101) at doses of 100 mg every 12 weeks (Q12W), 400 mg every 24 weeks (Q24W), and 100 mg every 24 weeks (Q24W), or placebo administered SC. In order to maintain the blinding of different doses, all participants will receive 2 SC injections at each dosing visit. This study consists of a Screening/Run-In Period (approximately 4 weeks), Treatment Period (up to 60 weeks with a minimum of 24 weeks) and Follow-up Period (ending approximately 16 weeks after the last administration of study intervention).

03

Conditions studied

  • Severe Asthma

Keywords

  • VALIANT
  • Respiratory Tract Diseases
  • Bronchial Diseases
  • Asthma
  • Lung Diseases
  • Uncontrolled Asthma
  • Severe Asthma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed, dated, and received a copy of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written form (ICF).
  • Age 18 to 80 years of age (inclusive) at the time of consent.
  • Physician-diagnosed asthma for at least 12 months prior to Visit 1.
  • Participant has evidence of bronchodilator (BD) reversibility as documented by either historical reversibility (within 12 months prior to study entry) or reversibility during screening.
  • Documented treatment with a total daily dose of either medium or high dose inhaled (ICS) for at least 3 months. Participants on medium dose ICS must also have been taking at least one additional maintenance asthma controller medication for at least 3 months.
  • Documented history of asthma exacerbation(s) within 12 months of Visit 1.
  • Asthma Control Questionnaire-6 (ACQ-6) score greater than or equal to (>=) 1.5 at screening and randomization.
  • Participant must have a pre-BD value of >=30 percent (%) and \<=80% predicted at Screening.
  • Minimum compliance with daily diary and background asthma medication(s) as captured in the daily diary during the Run-in Period.
  • Agrees to follow the required techniques/methods.
  • Female or male participant agrees not to donate eggs or sperm, respectively, for a period of 120 days after the last dose of the study drug intervention or at the Final Visit, whichever occurs last.

Exclusion criteria

Exclusion Criteria:

  • Inpatient hospitalization due to asthma at any time within 4 weeks prior to Visit 1 or during the Screening/Run-in Period.
  • Previous exposure to verekitug (UPB-101) or known allergy/sensitivity to any of its .
  • Previous biologics, including those for asthma treatment, for which the appropriate is not fulfilled prior to Visit 1. If the half-life is not known, a 24-week washout period prior to Visit 1 should be applied.
  • Allergen immunotherapy (unless maintenance dose) within 12 weeks prior to Visit 1 or plans to begin therapy or change dosing during the study.
  • For participants taking oral (OCS), the dose has not been stable for at least 2 weeks prior to Visit 1 and/or is >10 milligram (mg) daily, or >20 mg every other day.
  • Evidence of active or suspected bacterial, viral, fungal, or parasitic infections within 2 weeks prior to Visit 1.
  • History compatible with or diagnosis of a parasitic infection and has not been treated or has not responded to standard of care therapy.
  • Current tobacco smokers, nicotine vapers (including electronic cigarettes), snuff users or participants with a smoking history >=10 pack years. (Former nicotine smokers with a smoking history of \<10 pack years, former nicotine vapers and former snuff users must have stopped for at least 6 months prior to Visit 1 to be eligible).
  • Positive coronavirus disease 2019 (COVID-19) test with lower respiratory tract symptoms within 28 days before Visit 1.
  • Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study or unwilling to use adequate , if of and sexually active.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    Verekitug (UPB-101): 100 mg Q12W / Placebo

    Participants will receive 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams \[mg\] of verekitug \[UPB-101\]) and 2.0 mL of placebo subcutaneously in two separate injections every 12 weeks up to Week 48.

    Drug: Verekitug (UPB-101) · Drug: Placebo

  • Experimental
    Verekitug (UPB-101): 400 mg Q24W / Placebo

    Participants will receive 2.0 mL of verekitug (UPB-101) formulated solution (containing 400 mg of verekitug \[UPB-101\]) and 0.5 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.

    Drug: Verekitug (UPB-101) · Drug: Placebo

  • Experimental
    Verekitug (UPB-101): 100 mg Q24W / Placebo

    Participants will receive 0.5 mL of verekitug (UPB-101) formulated solution (containing 100 mg of verekitug \[UPB-101\]) and 2.0 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.

    Drug: Verekitug (UPB-101) · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive 0.5 mL of matching placebo and 2.0 mL of matching placebo subcutaneously in two separate injections every 12 weeks up to Week 48.

    Drug: Placebo

Interventions

  • Verekitug (UPB-101) formulated solution

  • DrugPlacebo

    Verekitug (UPB-101) matching placebo

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate (AAER)

    An asthma exacerbation is defined as a worsening of asthma that required treatment with systemic (oral or intravenous) corticosteroids for at least three consecutive days or a single depo-injectable dose of corticosteroids or an emergency room (ER) or urgent care visit that required systemic corticosteroids or an admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for greater than or equal to 24 hours.

    Time frame: Baseline up to Week 60

Secondary outcomes

  1. Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) of Pre-bronchodilator (Pre-BD) to Week 60

    Spirometry will be performed pre-bronchodilator (BD) to measure lung function. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.

    Time frame: Baseline to Week 60

  2. Change from Baseline in Fractional exhaled nitric oxide (FeNO) to Week 60

    Standardized single breath FeNO test is performed to evaluate airway inflammation.

    Time frame: Baseline to Week 60

  3. Change from Baseline in Asthma Control Questionnaire-6 (ACQ-6) to Week 60

    ACQ-6 is a participant-reported questionnaire to assess asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

    Time frame: Baseline to Week 60

  4. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to Week 64

07

Study locations

155 sites
  • AllerVie Clinical Research
    Birmingham, Alabama 35209, United States
  • Kern Research, Inc.
    Bakersfield, California 93301, United States
  • Velocity Clinical Research - Lafayette LA
    Los Angeles, California 70508, United States
  • Newport Native MD Inc
    Newport Beach, California 92663, United States
  • California Medical Research Associates Inc.
    Northridge, California 91324, United States
  • Integrated Research of Inland Inc
    Upland, California 91786, United States
  • Allergy & Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • Allianz Research Institute
    Westminster, California 92683, United States
  • Woodland Clinic Medical Group
    Woodland, California 95695, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Advance Pharma Research
    Cutler Bay, Florida 33189, United States
  • Unique Clinical Trials
    Doral, Florida 33172, United States
  • Health and Life Research Institute, LLC
    Miami, Florida 33155, United States
  • Phoenix Medical Research
    Miami, Florida 33165, United States
  • Research Institute of South Florida
    Miami, Florida 33173, United States
  • Nouvelle Clinical Research
    Miami, Florida 33189, United States
  • Anderson Allergy And Asthma, PA
    Orlando, Florida 32806, United States
  • Edward Jenner Research Group, LLC
    Plantation, Florida 33317, United States
  • R&B Medical Center
    Tampa, Florida 33614, United States
  • Clinical Site Partners dba Flourish research
    Winter Park, Florida 32789, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Winter Park, Florida 32789, United States
  • Pivotal Research Solutions
    Stonecrest, Georgia 30038, United States
  • RNA America Health Sciences
    Sugar Hill, Georgia 30518, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Velocity Clinical Research - Meridian
    Meridian, Idaho 83642, United States
  • Howard County Center for Lung and Sleep Medicine LLC
    Columbia, Maryland 21044, United States
  • Chesapeake Clinical Research Inc
    White Marsh, Maryland 21162, United States
  • Exordia Medical Research Inc
    Fall River, Massachusetts 02723, United States
  • Pulmonary Research Institute of Southeast Michigan
    Farmington Hills, Michigan 48336, United States
  • AA Medical Research Center
    Flint, Michigan 48504, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • M3 Wake Research
    Las Vegas, Nevada 89106, United States
  • Urban Health Plan INC
    The Bronx, New York 10459, United States
  • Advanced Respiratory and Sleep Medicine LLC
    Huntersville, North Carolina 28078, United States
  • Summit Research Group LLC
    Munroe Falls, Ohio 44262, United States
  • Toledo Institute of Clinical Research Inc
    Toledo, Ohio 43617, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Portland Clinical Research
    Clackamas, Oregon 97015, United States
  • Velocity Clinical Research - Medford
    Medford, Oregon 97504, United States
  • Velocity Clinical Research - Anderson
    Anderson, South Carolina 29621, United States
  • WR-Notus Clinical Research, LLC
    Charleston, South Carolina 29414, United States
  • Velocity Clinical Research - Spartanburg
    Spartanburg, South Carolina 29303, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Horizon Clinical Research
    Cypress, Texas 77429, United States
  • Alina Clinical Trials, LLC
    Dallas, Texas 75225, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • El Paso Pulmonary Association
    El Paso, Texas 79902, United States
  • Greater Houston Memorial Pulmonary and Sleep
    Houston, Texas 77008, United States
  • Sante Clinical Research
    Kerrville, Texas 78028, United States
  • Mayflower Clinical
    Marble Falls, Texas 02747, United States
  • Metroplex Pulmonary and Sleep Center Drive
    McKinney, Texas 75069, United States
  • Element Research Group
    San Antonio, Texas 78258, United States
  • DM Clinical Tomball
    Tomball, Texas 77375, United States
  • Velocity Clinical Research
    West Jordan, Utah 84088, United States
  • University of Wisconsin--Madison
    Madison, Wisconsin 53792, United States
  • IERIM Instituto de Enfermedades Respiratorias e Investigacion Medica
    San Juan Bautista, Buenos Aires 1888, Argentina
  • Centro de Medicina Respiratoria
    Concepción del Uruguay, Entre Ríos Province E3260, Argentina
  • Fundacion Scherbovsky
    Mendoza, Mendoza Province 5500, Argentina
  • Fundacion Estudios Clinicos (FECLIN)
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto Especialidades de la Salud Rosario
    Rosario, Santa Fe Province 2000, Argentina
  • Office of Hector H. Altieri MD
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigaciones En Patologias Respiratorias
    San Miguel de Tucumán, Tucumán Province CP T4000IAP, Argentina
  • CARE: Centro de Alergia y Enfermedades Respiratorias
    Buenos Aires, C1414AIF, Argentina
  • Fundacion Respirar - Centro Medico Dra. De Salvo
    Buenos Aires, C1426ABP, Argentina
  • Fundacion Cidea
    Caba, C1121ABE, Argentina
  • InAER
    CABA, C1425BEN, Argentina
  • Centro Dr. Lazaro Langer Privado Medicina del Aparato Respiratorio
    Córdoba, X5003DCE, Argentina
  • INSARES
    Mendoza, 5500, Argentina
  • Centro Medico Dharma
    Mendoza, M5500, Argentina
  • MHAT "Rahila Angelova" Pernik
    Pernik, 2300, Bulgaria
  • UMHAT Sveti Georgi
    Plovdiv, 4001, Bulgaria
  • Ambulatory For Specialized Outpatient Medical Care - Individual Practice - Dr. Nikolay Evgeniev Ruse Ltd
    Rousse, 7000, Bulgaria
  • Medical Center Excelsior
    Sofia, 1407, Bulgaria
  • Medical Center HERA EOOD
    Sofia, 1510, Bulgaria
  • DCC Convex
    Sofia, 1680, Bulgaria
  • Medconsult Pleven
    Sofia, 1756, Bulgaria
  • Medical center Pulmovizhyn
    Sofia, 1756, Bulgaria
  • Medical Center New Rehabilitation Center EOOD
    Stara Zagora, 6001, Bulgaria
  • MC Zdrave 1
    Vratsa, 3320, Bulgaria
  • Dynamic Drug Advancement
    Ajax, Ontario L1S 2J5, Canada
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1H 1E4, Canada
  • Toronto Allergists
    Toronto, Ontario M5G1E2, Canada
  • Winchester Hospital
    Winchester, Ontario K0C 2K0, Canada
  • Fundacion Medica San Cristobal
    Santiago, Santiago Metropolitan 7630226, Chile
  • Icegclinic
    Santiago, Santiago Metropolitan 8241479, Chile
  • Centro Médico BIOREUMA
    Concepción, 4070280, Chile
  • CIMER
    Providencia, 7500657, Chile
  • Sociedad medica Sy G Limitada
    Santiago, 7501126, Chile
  • Fakultni Nemocnice u Sv. Anny v Brne
    Brno, Czech Republic 602 00, Czechia
  • Alergologie a imunologie Hofstetr Alois MUDr. s.r.o.
    Jihlava, Czech Republic 586 01, Czechia
  • Plicni Stredisko Teplice S.R.O
    Teplice, Czech Republic 415 01, Czechia
  • PNEUMOLOGIE VARNSDORF s.r.o.
    Varnsdorf, Czech Republic 407 47, Czechia
  • KPPK Studienzentrum
    Koblenz, Rhineland-Palatinate 56068, Germany
  • POIS Sachsen GmbH
    Leipzig, Saxony 04347, Germany
  • RCMS/Lungenpraxis Hohenzollerndamm
    Berlin, 10717, Germany
  • Velocity Clinical Research Germany , Berlin
    Berlin, 10787, Germany
  • Pneumologisches Studienzentrum
    Berlin, 10961, Germany
  • ME Clinical Respiratory Research Hamburg GmbH
    Hamburg, 22299, Germany
  • IKF Pneumologie Frankfurt, Clinical Research Center Respiratory Diseases
    Hessen, 60596, Germany
  • IKF Pneumologie GmbH & Co. KG
    Mainz, 55128, Germany

Showing the first 100 of 155 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025 Jan;134(1):9-18. doi: 10.1016/j.anai.2024.09.016. Epub 2024 Oct 10. PubMed 39393433 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Dec 2025, 21 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 21 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2023
First posted
Jan 9, 2024
StartActual
Feb 27, 2024
Primary completionActual
Dec 16, 2025
CompletionActual
Mar 19, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06196879
Lead sponsor
Upstream Bio Inc.
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Feb 27, 2024
Primary completion
Dec 16, 2025
Completion
Mar 19, 2026
Last update
May 1, 2026

Study contacts

Justin Salciccioli, MD
study director · Upstream Bio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verekitug

Start the discussion